USCOM LIMITED — Regulatory Filings 2014

Jun 22, 2014

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

Uscom Manufactures First Australian BPplus Device

Monday 23rd of June 2014: Uscom (ASX code: UCM)

Uscom Limited, an Australian publicly listed medical device Company, is pleased to announce the manufacture of the first Uscom BP+ unit at its head office in Circular Quay, Sydney. The Uscom BP+ is a practice leading, high fidelity, central blood pressure and pulse pressure wave analysis technology based on patent protected suprasystolic oscillometric blood pressure measurements specialised for advanced assessment of hypertension and heart failure.

The first production run of 180 BP+ units, is the final step in the acquisition and integration of Pulsecor assets announced to market in June 2013, and the first step in the global sales and marketing by Uscom of the Uscom BP+. The process has involved the transfer of ownership of all Pulsecor Limited assets, application for and granting of new regulatory approvals, development of new manufacturing specifications and processes, and ultimately assembly of components into the first Uscom BP+ device. The BP+ has both CE Mark and FDA 510K status. Uscom now manufactures 2 premium cardiovascular devices at its Australian centre of operations - the USCOM 1A and now the BP+.

Concurrently management have been appointing new distributors for the BP+ and developing new marketing collateral. Seven new distributors have been appointed covering the UK and China, and they are preparing to sell the BP+ as soon as the relevant regional regulatory approvals permit. Further partnership discussions are continuing, and potential distributors for the remaining global markets are being reviewed.

Executive Chairman of Uscom, Dr Rob Phillips said, “This is a significant milestone for Uscom and a success story for the Australian Medical Device Industry. Uscom now owns and manufactures within Australia two practice leading, noninvasive cardiovascular technologies being exported and sold into global markets. The manufacture of these two devices effectively doubles the size of Uscom, and the strategic power associated with this is difficult to estimate. Our current objectives are to rapidly grow global distribution for both of these products and to exploit the powerful revenue opportunities this creates. We anticipate our new distribution will continue to uptake over the next 18 months and reach optimal revenue impact in mid 2015.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the approach to diagnosis and treatment of cardiovascular diseases, including hypertension, heart failure and advanced haemodynamics. The two products are also integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the BP+. The devices are both clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Blood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au